Strategic unmet needs Delpor’s year-long sustained release platform targets adherence to therapies with short half-lives, presenting a clear sales opportunity to pharma/biotech companies seeking to improve patient compliance and outcomes in CNS, chronic pain, autoimmune diseases, and other conditions.

Clinical validation Clinical phase achievements, including a phase 2 study for DLP-114 and positive safety/PK data, provide a compelling value proposition for partnering with manufacturers aiming to extend dosing intervals and differentiate their products.

Funding signals Past NIH/NIMH grant support and a track record of external funding indicate credibility and potential for co-development or translational collaborations with researchers, CROs, and funding-focused partners.

Payer and physician interest Positive market research from over 200 high-prescribing physicians and several U.S. and EU payers suggests a receptive environment for reimbursement-focused partnerships and early access programs.

Global therapeutic expansion Delpor is pursuing CNS/psychiatric, chronic pain, autoimmune, and other indications, offering multiple collaboration avenues across therapeutic areas and potential for multi-indication licensing deals.